

Rheumatoid Arthritis [2017]: Bulletin #2

https://marketpublishers.com/r/R06B14BDB1AEN.html

Date: August 2017

Pages: 0

Price: US\$ 1,045.00 (Single User License)

ID: R06B14BDB1AEN

Abstracts

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of rheumatoid arthritis (RA). Topics covered in this update bulletin include expert opinions on; Johnson & Johnson announcing the FDA's rejection of Plivensia (sirukumab); Can-Fite concluding its cardiodynamic trial for piclidenoson (CF 101) and being given approval to begin a global Phase III trial in patients with RA; and AbbVie announcing data from the Phase III SELECT-NEXT trial for upadacitinib in patients with RA.

Business Questions:

How do KOLs regard Plivensia and what are its chances of coming to market?

How would Plivensia fare against other IL-6 inhibitors for RA?

According to KOLs, what lies ahead for IL-6 inhibitors as a class?

How do KOLs view the piclidenoson ACRobat study versus methotrexate?

If approved, how would piclidenoson be prescribed?

Does upadacitinib differentiate itself from other JAK inhibitors?



I would like to order

Product name: Rheumatoid Arthritis [2017]: Bulletin #2

Product link: https://marketpublishers.com/r/R06B14BDB1AEN.html

Price: US\$ 1,045.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/R06B14BDB1AEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970